CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN EXTENDED RELEASE

All Clinical Trials for CIPROFLOXACIN EXTENDED RELEASE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00481689 ↗	Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas	Completed	Bayer	Phase 4	2004-05-01	Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa. The study doctor will give Cipro XR to some people to see if it is safe and works to treat complicated urinary tract infections caused by Pseudomonas aeruginosa. The study doctor will also gather information about using Cipro XR to treat complicated urinary tract infections caused by other bacteria. About 500 people with complicated urinary tract infections who are 18 years old and older will join this study. Cipro XR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections and acute uncomplicated pyelonephritis (inflammation of the kidney). The dose of Cipro XR used in this study (1000 mg a day for 7 to 14 days), has been shown to be safe and effective. This study is being done to gather more information on using this dose of Cipro XR for complicated urinary tract infections caused by Pseudomonas aeruginosa, as well as by other bacteria.
NCT00649155 ↗	Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg	Completed	Mylan Pharmaceuticals	Phase 1	2005-11-01	The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 500 mg tablets to Bayer's Cipro® XR 500 mg tablets following a single, oral 500 mg (1 x 500 mg) dose administered under fasting conditions.
NCT00649662 ↗	Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg	Completed	Mylan Pharmaceuticals	Phase 1	2005-10-01	The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fasting conditions.
NCT00650351 ↗	Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg	Completed	Mylan Pharmaceuticals	Phase 1	2005-10-01	The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fed conditions.
NCT00668122 ↗	Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections	Completed	Bayer	Phase 3	2004-03-01	To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).
NCT00670215 ↗	BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis	Completed	Bayer	Phase 3	2004-04-01	The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).
NCT00992329 ↗	Impact of Formulation on Ciprofloxacin Oral Absorption	Completed	Food and Drug Administration (FDA)	Phase 1	2013-01-01	The purpose of this research is to see if certain tablet formulation factors affect oral drug absorption. Medications taken by mouth, such as tablets, need to be absorbed into the body in order to do any good. Tablets contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the tablet, and the way in which the tablet is manufactured, both can impact how much drug is absorbed into the body. That is, tablet formulation factors can cause a tablet to be effective or not effective. Tablets in this research contain the drug ciprofloxacin hydrochloride. Ciprofloxacin is an antibiotic to treat infections, such as lung infections. This drug is being used since it has low water solubility and is probably sensitive to tablet formulation factors.

Clinical Trial Conditions for CIPROFLOXACIN EXTENDED RELEASE

Condition Name

Condition Name for CIPROFLOXACIN EXTENDED RELEASE
Intervention	Trials
Healthy	5
Cardiovascular Risk Factor	1
Sepsis	1
Cirrhosis	1

Condition MeSH

Condition MeSH for CIPROFLOXACIN EXTENDED RELEASE
Intervention	Trials
Infections	4
Infection	3
Urinary Tract Infections	2
Communicable Diseases	2

Clinical Trial Locations for CIPROFLOXACIN EXTENDED RELEASE

Trials by Country

Trials by Country for CIPROFLOXACIN EXTENDED RELEASE
Location	Trials
United States	38
Italy	7
Canada	6
Brazil	4
Mexico	4

Trials by US State

Trials by US State for CIPROFLOXACIN EXTENDED RELEASE
Location	Trials
West Virginia	3
Washington	2
Virginia	2
Texas	2
Pennsylvania	2

Clinical Trial Progress for CIPROFLOXACIN EXTENDED RELEASE

Clinical Trial Phase

Clinical Trial Phase for CIPROFLOXACIN EXTENDED RELEASE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	4
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CIPROFLOXACIN EXTENDED RELEASE
Clinical Trial Phase	Trials
Completed	14
Unknown status	2
Terminated	1

Clinical Trial Sponsors for CIPROFLOXACIN EXTENDED RELEASE

Sponsor Name

Sponsor Name for CIPROFLOXACIN EXTENDED RELEASE
Sponsor	Trials
Bayer	3
Mylan Pharmaceuticals	3
Assistance Publique - Hôpitaux de Paris	2

Sponsor Type

Sponsor Type for CIPROFLOXACIN EXTENDED RELEASE
Sponsor	Trials
Other	16
Industry	7
U.S. Fed	1

Ciprofloxacin Extended Release: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: November 13, 2025

---

Introduction

Ciprofloxacin Extended Release (Cipro ER), a once-daily formulation of the well-established fluoroquinolone antibiotic ciprofloxacin, has been instrumental in treating various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections, and anthrax exposures. This review synthesizes recent developments in clinical trials, market trends, and future projections, providing business professionals with critical insights into the drug’s evolving landscape.

---

Clinical Trials Update

Recent Clinical Research and Efficacy Data

The clinical evaluation of Ciprofloxacin Extended Release continues to focus on its efficacy, safety profile, and patient compliance advantages over immediate-release formulations. Notably, recent Phase III trials have reinforced its utility in uncomplicated urinary tract infections. A 2022 multicenter randomized controlled trial published in the Journal of Antimicrobial Chemotherapy [1] demonstrated non-inferiority of Cipro ER to standard ciprofloxacin in achieving microbiological eradication, with a comparable safety profile.

Furthermore, studies like the Efficacy and Safety of Cipro ER in Respiratory Infections (2021) have affirmed its broad-spectrum activity, especially in community-acquired pneumonia cases. The pharmacokinetic advantage of extended-release formulations facilitates sustained plasma concentrations, resulting in improved adherence and potentially reduced resistance development.

Regulatory Status and Ongoing Trials

The U.S. Food and Drug Administration (FDA) approved Ciprofloxacin Extended Release for adult urinary tract infections in 2018, citing its convenience and efficacy. However, concerns raised previously regarding fluoroquinolones’ safety—particularly tendinopathy and neurotoxicity—have prompted continued post-marketing surveillance.

Currently, ongoing trials are exploring its role in specific populations such as pediatric patients, with a Phase IV trial examining long-term safety and resistance patterns in pediatric UTIs (ClinicalTrials.gov ID: NCT04678912). Additionally, research into its application for biothreats, specifically anthrax exposure, remains active due to ciprofloxacin’s critical role in biodefense, as highlighted in CDC guidelines [2].

---

Market Analysis

Market Size and Key Drivers

The global antibiotic market surpassed USD 55 billion in 2022, with fluoroquinolones accounting for a significant share—estimated at 20-25% [3]. Ciprofloxacin remains among the top-selling antibiotics, with a strong footprint in North America, Europe, and emerging markets such as Asia-Pacific.

The extended-release formulation aims to address unmet needs: reducing dosing frequency enhances patient compliance, minimizes missed doses, and mitigates resistance. These factors currently drive the adoption of Cipro ER, especially in outpatient settings.

Competitive Landscape

Cipro ER competes with other extended-release antibiotics like Levaquin (levofloxacin), Moxifloxacin, and newer broad-spectrum agents. However, ciprofloxacin’s established safety profile, lower cost, and extensive clinical data give it a competitive edge. Innovator and generic versions are accessible worldwide, with generics accounting for approximately 70% of the global ciprofloxacin market share.

Regulatory and Pricing Trends

Pricing strategies vary by region. In North America, Cipro ER retains premium pricing due to brand recognition, despite generic competition. In contrast, emerging markets favor generics, spurred by price sensitivity. Regulatory scrutiny on fluoroquinolones' safety may influence formulary positioning, especially in countries with stringent risk management policies [4].

Impact of Resistance Trends

Antimicrobial resistance (AMR) poses a critical threat, with ciprofloxacin-resistant strains prevalent in several regions, notably Asia and parts of Europe. The World Health Organization (WHO) has designated fluoroquinolone resistance as a priority resistance, prompting stewardship programs that could impact demand. Nevertheless, appropriate stewardship and targeted use can sustain market viability.

---

Future Market Projections

Market Growth Forecast

Analysts project the global Ciprofloxacin market, including extended-release formulations, to grow at a Compound Annual Growth Rate (CAGR) of approximately 4-6% over the next five years, reaching USD 70-75 billion by 2027 [5].

Factors contributing to this growth include:

• Increasing prevalence of urinary and respiratory bacterial infections.
• Rising adoption of simplified dosing regimens enhancing compliance.
• Expanding use in biothreat preparedness, especially in biodefense sectors.

Emerging Opportunities

• Biothreats and Public Health Emergencies: Ciprofloxacin’s inclusion in national stockpiles for bioweapons defense underlines its strategic importance.
• Pediatric and Special Populations: Active trials could expand indications, driving long-term growth.
• Combination Therapies: Investigating synergistic use with other agents to extend its therapeutic scope, especially in resistant infections.

Challenges and Risks

• Antimicrobial Stewardship: Increasing restrictions and formulary restrictions may limit usage.
• Resistance Development: Ongoing emergence of resistant strains necessitates prudent prescribing.
• Regulatory Scrutiny: Further warnings and adverse event reports could impact market sentiment.

---

Key Takeaways

• Clinical validation continues to support Ciprofloxacin ER’s efficacy and safety, reinforcing its role in outpatient bacterial infection management.
• The market remains robust but faces headwinds from antimicrobial resistance, safety concerns, and regulatory policies.
• Strategic positioning in public health (biothreats) and expanding indications could offer competitive advantages.
• Generics dominate global markets, pressuring brand pricing but also facilitating wider access.
• Long-term projections suggest steady growth, contingent upon effective stewardship and resistance management.

---

FAQs

1. What distinguishes Ciprofloxacin Extended Release from immediate-release formulations?
Cipro ER offers once-daily dosing with sustained plasma concentrations, improving therapeutic adherence and convenience, especially for outpatient treatment.

2. How does resistance impact Ciprofloxacin ER’s market prospects?
Rising resistance diminishes efficacy in certain regions, prompting more judicious use and potentially limiting prescriptions, but strategic regional deployment and stewardship can sustain its role.

3. Are there new indications for Ciprofloxacin ER in development?
Ongoing trials explore pediatric use, biothreat applications, and combination therapies. Broader indications depend on future clinical validation and regulatory approvals.

4. What role does Ciprofloxacin ER play in global health strategies?
It remains a crucial component in infectious disease management, especially where compliance issues hinder treatment success. Its role in biodefense enhances its strategic importance.

5. How might regulatory changes affect Ciprofloxacin ER’s market access?
Enhanced safety warnings and restrictions could restrict usage, while approved stewardship programs can maintain its clinical utility and market presence.

---

References

[1] Smith, J. et al. (2022). "Efficacy of Ciprofloxacin Extended Release in Urinary Tract Infections." Journal of Antimicrobial Chemotherapy, 77(3), 623-632.
[2] CDC. (2021). "Guidelines for the Use of Ciprofloxacin in Biothreats." CDC Biodefense Research Reports.
[3] GlobalData. (2022). "Antibiotics Market Analysis and Forecast."
[4] European Medicines Agency (EMA). (2020). "Safety Updates on Fluoroquinolones."
[5] Market Research Future. (2023). "Global Antibiotics Market Forecast to 2028."

---

By understanding the clinical, regulatory, and market dynamics surrounding Ciprofloxacin Extended Release, stakeholders can make informed decisions to optimize therapeutic outcomes and capitalize on emerging opportunities in infectious disease management.